



# SAFETY DATA SHEET

Revision date 13-Jun-2025

Version 3

Page 1 / 16

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

**Product Name** Lidocaine hydrochloride and epinephrine injection, solution (Hospira, Inc.)  
**Product Code(s)** PZ03472  
**Synonyms** Lignoocaine with epinephrine  
**Trade Name:** Not applicable  
**Chemical Family:** Not determined

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** Pharmaceutical product anesthetic agent

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

**E-mail address** pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

**Emergency Telephone** Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

GHS - Classification: This substance is classified as not hazardous according to regulation (EC) 1272/2008 [CLP].

#### OSHA Classification

**Hazards not otherwise classified (HNOC)**  
Not applicable

**Hazards classified under paragraph (d)(1)(ii) of 1910.1200**  
Not applicable

### 2.2. Label elements

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 2 / 16

Version 3

## Signal word

Not classified

## Hazard statements

Not classified in accordance with international standards for workplace safety.

## 2.3. Other hazards

### Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

## PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

## Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

## Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1 Substances

#### Substances

Not applicable

### 3.2 Mixtures

#### Hazardous

| Chemical name                               | Weight-% | REACH registration number | EC No (EU Index No)                     | Classification according to Regulation (EC) No. 1272/2008 [CLP] | Specific concentration limit (SCL)                                                                               | M-Factor          | M-Factor (long-term) |
|---------------------------------------------|----------|---------------------------|-----------------------------------------|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-------------------|----------------------|
| Lidocaine Hydrochloride (CAS #: 73-78-9)    | <=2      |                           | 200-803-8                               | Acute Tox.4 (H302)                                              | Not classified                                                                                                   | No data available | No data available    |
| Sodium metabisulfite USP (CAS #: 7681-57-4) | <0.1     |                           | 231-673-0 (016-063-00-2)                | Acute Tox. 4 (H302)<br>Eye Dam. 1 (H318)                        | Not classified                                                                                                   | No data available | No data available    |
| Epinephrine hydrochloride (CAS #: 329-63-5) | < 1      |                           | 206-346-0                               | Not classified                                                  | Not classified                                                                                                   | No data available | No data available    |
| Sodium hydroxide (CAS #: 1310-73-2)         | < 0.1    | -                         | 215-185-5 (011-002-00-6)                | Skin Corr.1A (H314)                                             | Eye Irrit. 2 :: 0.5%<=C<2%<br>Skin Corr. 1A :: C>=5%<br>Skin Corr. 1B :: 2%<=C<5%<br>Skin Irrit. 2 :: 0.5%<=C<2% | No data available | No data available    |
| + Hydrochloric Acid (CAS #: 7647-01-0)      | **       | -                         | 231-595-7 (017-002-00-2) (017-002-01-X) | Press. Gas<br>Skin Corr. 1A (H314)                              | Eye Irrit. 2 :: 10%<=C<25%<br>Skin Corr. 1B ::                                                                   | No data available | No data available    |

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 3 / 16

Version 3

|  |  |  |  |                        |                                                                    |  |  |
|--|--|--|--|------------------------|--------------------------------------------------------------------|--|--|
|  |  |  |  | Acute Tox. 3<br>(H331) | C>=25%<br>Skin Irrit. 2 ::<br>10%<=C<25%<br>STOT SE 3 ::<br>C>=10% |  |  |
|--|--|--|--|------------------------|--------------------------------------------------------------------|--|--|

NonHazardous

| Chemical name                         | Weight-% | REACH<br>registration<br>number | EC No (EU<br>Index No) | Classification<br>according to<br>Regulation<br>(EC) No.<br>1272/2008<br>[CLP] | Specific<br>concentration<br>limit (SCL) | M-Factor             | M-Factor<br>(long-term) |
|---------------------------------------|----------|---------------------------------|------------------------|--------------------------------------------------------------------------------|------------------------------------------|----------------------|-------------------------|
| Water<br>(CAS #: 7732-18-5)           | *        | -                               | 231-791-2              | Not classified                                                                 | Not classified                           | No data<br>available | No data<br>available    |
| SODIUM CHLORIDE<br>(CAS #: 7647-14-5) | *        | -                               | 231-598-3              | Not classified                                                                 | Not classified                           | No data<br>available | No data<br>available    |

**Full text of H- and EUH-phrases: see section 16**

Acute Toxicity Estimate

| Chemical name                         | Oral LD50 mg/kg | Dermal LD50<br>mg/kg | Inhalation LC50 - 4<br>hour - dust/mist - mg/L | Inhalation LC50 - 4<br>hour - vapor - mg/L | Inhalation LC50 - 4<br>hour - gas - ppm |
|---------------------------------------|-----------------|----------------------|------------------------------------------------|--------------------------------------------|-----------------------------------------|
| Water<br>7732-18-5                    | 89838.9         | No data available    | No data available                              | No data available                          | No data available                       |
| Lidocaine Hydrochloride<br>73-78-9    | 317             | No data available    | No data available                              | No data available                          | No data available                       |
| SODIUM CHLORIDE<br>7647-14-5          | 3550            | 10000                | No data available                              | No data available                          | No data available                       |
| Sodium metabisulfite USP<br>7681-57-4 | 1310            | 2000                 | No data available                              | No data available                          | No data available                       |
| Sodium hydroxide<br>1310-73-2         | 325             | 1350                 | No data available                              | No data available                          | No data available                       |
| + Hydrochloric Acid<br>7647-01-0      | 238             | 5010                 | No data available                              | No data available                          | 563.3022                                |

This product does not contain candidate substances of very high concern at a concentration  $\geq 0.1\%$  (Regulation (EC) No. 1907/2006 (REACH), Article 59).

## Additional information

+ Substance with a Union workplace exposure limit

\* Proprietary

\*\* to adjust pH

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

#### Inhalation

Remove to fresh air. Seek immediate medical attention/advice.

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 4 / 16

Version 3

|                     |                                                                                                                                                                                    |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Eye contact</b>  | Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.                                                               |
| <b>Skin contact</b> | Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.                                                                            |
| <b>Ingestion</b>    | Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately. |

## 4.2. Most important symptoms and effects, both acute and delayed

|                                            |                                                                                                                                                    |
|--------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Most important symptoms and effects</b> | For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information. |
|--------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|

## 4.3. Indication of any immediate medical attention and special treatment needed

|                           |       |
|---------------------------|-------|
| <b>Note to physicians</b> | None. |
|---------------------------|-------|

## **Section 5: FIRE-FIGHTING MEASURES**

### 5.1. Extinguishing media

|                                     |                                                           |
|-------------------------------------|-----------------------------------------------------------|
| <b>Suitable Extinguishing Media</b> | Dry chemical, CO2, alcohol-resistant foam or water spray. |
|-------------------------------------|-----------------------------------------------------------|

### 5.2. Special hazards arising from the substance or mixture

|                                                   |                                                           |
|---------------------------------------------------|-----------------------------------------------------------|
| <b>Specific hazards arising from the chemical</b> | Fine particles (such as mists) may fuel fires/explosions. |
|---------------------------------------------------|-----------------------------------------------------------|

|                                      |                                                              |
|--------------------------------------|--------------------------------------------------------------|
| <b>Hazardous combustion products</b> | Formation of toxic gases is possible during heating or fire. |
|--------------------------------------|--------------------------------------------------------------|

#### **Explosion data**

|                                         |                           |
|-----------------------------------------|---------------------------|
| <b>Sensitivity to mechanical impact</b> | No information available. |
| <b>Sensitivity to static discharge</b>  | No information available. |

### 5.3. Advice for firefighters

|                                                                       |                                                                                                                                    |
|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| <b>Special protective equipment and precautions for fire-fighters</b> | Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment. |
|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|

## **Section 6: ACCIDENTAL RELEASE MEASURES**

### 6.1. Personal precautions, protective equipment and emergency procedures

|                                 |                                                                                                                          |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| <b>Personal precautions</b>     | Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure. |
| <b>For emergency responders</b> | Use personal protection recommended in Section 8.                                                                        |

### 6.2. Environmental precautions

|                                  |                                                                                                                              |
|----------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| <b>Environmental precautions</b> | Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release. |
|----------------------------------|------------------------------------------------------------------------------------------------------------------------------|

### 6.3. Methods and material for containment and cleaning up

|                                |                                                                                                  |
|--------------------------------|--------------------------------------------------------------------------------------------------|
| <b>Methods for containment</b> | Prevent further leakage or spillage if safe to do so.                                            |
| <b>Methods for cleaning up</b> | Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean |

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 5 / 16

Version 3

**Prevention of secondary hazards** spill area thoroughly.  
Clean contaminated objects and areas thoroughly observing environmental regulations.

## 6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## **Section 7: HANDLING AND STORAGE**

### 7.1. Precautions for safe handling

**Advice on safe handling** Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8).

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

### 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store as directed by product packaging.

### 7.3. Specific end use(s)

**Specific use(s)** Pharmaceutical drug product.

## **Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION**

### 8.1. Control parameters

#### **Exposure Limits**

Refer to available public information for specific member state Occupational Exposure Limits.

#### **Lidocaine Hydrochloride**

Pfizer OEL TWA-8 Hr: 300; STEL 2500 µg/m<sup>3</sup>, Skin

#### **SODIUM CHLORIDE**

Latvia

TWA: 5 mg/m<sup>3</sup>;

Russia

MAC: 5 mg/m<sup>3</sup>

#### **Sodium metabisulfite USP**

ACGIH TLV

TWA: 5 mg/m<sup>3</sup>

Denmark

TWA: 5 mg/m<sup>3</sup>;

STEL: 10 mg/m<sup>3</sup>;

France

5 mg/m<sup>3</sup>

Ireland

TWA: 5 mg/m<sup>3</sup>;

STEL: 15 mg/m<sup>3</sup> (calculated; thoracic fraction);

Spain

TWA-(VLA-ED): 5 mg/m<sup>3</sup>;

Switzerland

TWA-MAK: 5 mg/m<sup>3</sup>; inhalable dust

OSHA PEL

(vacated) TWA: 5 mg/m<sup>3</sup>

United Kingdom

TWA: 5 mg/m<sup>3</sup>;

STEL: 15 mg/m<sup>3</sup>;

#### **Sodium hydroxide**

ACGIH OEL (Ceiling)

2 mg/m<sup>3</sup>

ACGIH TLV

Ceiling: 2 mg/m<sup>3</sup>

Austria

TWA-TMW: 2 mg/m<sup>3</sup>; inhalable fraction

STEL-KZGW: 4 mg/m<sup>3</sup> (8 X 5 min); inhalable fraction

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 6 / 16

Version 3

|                            |                                                   |
|----------------------------|---------------------------------------------------|
| Bulgaria                   | TWA: 2.0 mg/m <sup>3</sup> ; alkaline aerosols    |
| Czech Republic             | 1 mg/m <sup>3</sup>                               |
|                            | Ceiling: 2 mg/m <sup>3</sup>                      |
| Denmark                    | Ceiling: 2 mg/m <sup>3</sup> ;                    |
| Estonia                    | TWA: 1 mg/m <sup>3</sup> ;                        |
|                            | STEL: 2 mg/m <sup>3</sup> ;                       |
| Finland                    | Ceiling: 2 mg/m <sup>3</sup> ;                    |
| France                     | 2 mg/m <sup>3</sup>                               |
| Hungary                    | TWA-AK: 1 mg/m <sup>3</sup> ;                     |
|                            | STEL-CK: 2 mg/m <sup>3</sup> ;                    |
| Ireland                    | STEL: 2 mg/m <sup>3</sup> ;                       |
| Ceiling Limit Value        | 2 mg/m <sup>3</sup>                               |
| Latvia                     | TWA: 0.5 mg/m <sup>3</sup> ;                      |
| Poland                     | TWA-NDS: 0.5 mg/m <sup>3</sup> ;                  |
|                            | STEL-NDSch: 1 mg/m <sup>3</sup> ;                 |
| Romania                    | TWA: 1 mg/m <sup>3</sup> ;                        |
|                            | STEL: 3 mg/m <sup>3</sup> ;                       |
| Slovakia                   | TWA: 2 mg/m <sup>3</sup> ;                        |
| Spain                      | STEL (VLA-EC): 2 mg/m <sup>3</sup> ;              |
| Switzerland                | TWA-MAK: 2 mg/m <sup>3</sup> ; inhalable dust     |
|                            | STEL-KZGW: 2 mg/m <sup>3</sup> ; inhalable dust   |
| OSHA PEL                   | TWA: 2 mg/m <sup>3</sup>                          |
|                            | (vacated) Ceiling: 2 mg/m <sup>3</sup>            |
| United Kingdom             | STEL: 2 mg/m <sup>3</sup> ;                       |
| <b>+ Hydrochloric Acid</b> |                                                   |
| ACGIH OEL (Ceiling)        | 2 ppm                                             |
| ACGIH TLV                  | Ceiling: 2 ppm                                    |
| Austria                    | TWA-TMW: 5 ppm;                                   |
|                            | TWA-TMW: 8 mg/m <sup>3</sup> ;                    |
|                            | STEL-KZGW: 10 ppm (8 X 5 min);                    |
|                            | STEL-KZGW: 15 mg/m <sup>3</sup> (8 X 5 min);      |
| Bulgaria                   | TWA: 5 ppm;                                       |
|                            | TWA: 8.0 mg/m <sup>3</sup> ;                      |
|                            | STEL: 10 ppm;                                     |
|                            | STEL: 15.0 mg/m <sup>3</sup> ;                    |
| Czech Republic             | 8 mg/m <sup>3</sup>                               |
|                            | Ceiling: 15 mg/m <sup>3</sup>                     |
| Denmark                    | STEL: 5 ppm;                                      |
|                            | STEL: 8 mg/m <sup>3</sup> ;                       |
| Estonia                    | TWA: 5 ppm;                                       |
|                            | TWA: 8 mg/m <sup>3</sup> ;                        |
|                            | STEL: 10 ppm;                                     |
|                            | STEL: 15 mg/m <sup>3</sup> ;                      |
| European Union             | TWA: 5 ppm;                                       |
|                            | TWA: 8 mg/m <sup>3</sup> ;                        |
|                            | STEL: 10 ppm;                                     |
|                            | STEL: 15 mg/m <sup>3</sup> ;                      |
| Finland                    | STEL: 5 ppm;                                      |
|                            | STEL: 7.6 mg/m <sup>3</sup> ;                     |
| Germany DFG                | TWA-MAK: 2 ppm; I(2);                             |
|                            | TWA-MAK: 3.0 mg/m <sup>3</sup> ; I(2);            |
|                            | Peak: 4 ppm;                                      |
|                            | Peak: 6 mg/m <sup>3</sup> ;                       |
| Germany TRGS               | TWA-AGW; 2 ppm (exposure factor 2);               |
|                            | TWA-AGW; 3 mg/m <sup>3</sup> (exposure factor 2); |
| Hungary                    | TWA-AK: 8 mg/m <sup>3</sup> ;                     |
|                            | TWA-AK: 5 ppm;                                    |

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 7 / 16

Version 3

|                                           |                                                                                                                                                                              |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ireland                                   | STEL-CK: 165 mg/m <sup>3</sup> ;<br>STEL-CK: 10 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>TWA: 5 ppm;<br>STEL: 10 ppm;<br>STEL: 15 mg/m <sup>3</sup> ;                           |
| Italy MDLPS                               | TWA: 5 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>STEL: 10 ppm;<br>STEL: 15 mg/m <sup>3</sup> ;                                                                                   |
| Ceiling Limit Value                       | 2 ppm<br>3.0 mg/m <sup>3</sup>                                                                                                                                               |
| Latvia                                    | TWA: 5 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>STEL: 10 ppm;<br>STEL: 15 mg/m <sup>3</sup> ;                                                                                   |
| Netherlands                               | TWA: 5 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>STEL: 10 ppm;<br>STEL: 15 mg/m <sup>3</sup> ;                                                                                   |
| Poland                                    | TWA-NDS: 5 mg/m <sup>3</sup> ;<br>STEL-NDSch: 10 mg/m <sup>3</sup> ;                                                                                                         |
| Romania                                   | TWA: 5 ppm;<br>TWA: 8 mg/m <sup>3</sup> ;<br>STEL: 10 ppm;<br>STEL: 15 mg/m <sup>3</sup> ;                                                                                   |
| Russia                                    | MAC: 5 mg/m <sup>3</sup>                                                                                                                                                     |
| Slovakia                                  | TWA: 5 ppm;<br>TWA: 8.0 mg/m <sup>3</sup> ;<br>Ceiling: 15 mg/m <sup>3</sup> ;                                                                                               |
| Spain                                     | TWA-(VLA-ED): 5 ppm;<br>TWA-(VLA-ED): 7.6 mg/m <sup>3</sup> ;<br>STEL (VLA-EC): 10 ppm;<br>STEL (VLA-EC): 15 mg/m <sup>3</sup> ;                                             |
| Switzerland                               | TWA-MAK: 2 ppm;<br>TWA-MAK: 3 mg/m <sup>3</sup> ;<br>STEL-KZGW: 4 ppm;<br>STEL-KZGW: 6 mg/m <sup>3</sup> ;                                                                   |
| U.S. - OSHA - Final PELs - Ceiling Limits | 5 ppm<br>7 mg/m <sup>3</sup>                                                                                                                                                 |
| OSHA PEL                                  | Ceiling: 5 ppm<br>Ceiling: 7 mg/m <sup>3</sup><br>(vacated) Ceiling: 5 ppm<br>(vacated) Ceiling: 7 mg/m <sup>3</sup>                                                         |
| United Kingdom                            | TWA: 1 ppm; gas and aerosol mist<br>TWA: 2 mg/m <sup>3</sup> ; gas and aerosol mist<br>STEL: 5 ppm; gas and aerosol mist<br>STEL: 8 mg/m <sup>3</sup> ; gas and aerosol mist |

## Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

## SODIUM CHLORIDE

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 8 / 16

Version 3

|                                          |                                                                                          |
|------------------------------------------|------------------------------------------------------------------------------------------|
| Pfizer Occupational Exposure Band (OEB): | OEB 1 (control exposure to the range of 1000ug/m <sup>3</sup> to 3000ug/m <sup>3</sup> ) |
| <b>Epinephrine hydrochloride</b>         |                                                                                          |
| Pfizer Occupational Exposure Band (OEB): | OEB 4 (control exposure to the range of 1ug/m <sup>3</sup> to <10ug/m <sup>3</sup> )     |

## 8.2. Exposure controls

|                                        |                                                                                                                                                                                                                                                                                                                                                                                                                 |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Engineering controls</b>            | Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.                                                                                                                                                |
| <b>Personal protective equipment</b>   | Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. |
| <b>Eye/face protection</b>             | Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).                                                                                                                                                                                                                                          |
| <b>Hand protection</b>                 | Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).                                                                                                                                                         |
| <b>Skin and body protection</b>        | Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).                                                                                                                                                                |
| <b>Respiratory protection</b>          | Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).                         |
| <b>Thermal hazards</b>                 | No information available.                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Environmental exposure controls</b> | No information available.                                                                                                                                                                                                                                                                                                                                                                                       |

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

|                                       |                           |
|---------------------------------------|---------------------------|
| <b>Appearance</b>                     | Solution                  |
| <b>Physical state</b>                 | Liquid                    |
| <b>Color</b>                          | Clear, colorless          |
| <b>Odor</b>                           | No information available. |
| <b>Odor threshold</b>                 | No information available  |
| <b>Property</b>                       | <b>Values</b>             |
| <b>Melting point / freezing point</b> | No data available         |



# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 9 / 16

Version 3

|                                                          |                          |
|----------------------------------------------------------|--------------------------|
| Boiling point or initial boiling point and boiling range | No data available        |
| Flammability (solid, gas)                                | No data available        |
| Lower and upper explosion limit/flammability limit       |                          |
| Lower explosion limit                                    | No data available        |
| Upper explosion limit                                    | No data available        |
| Flash point                                              | No data available        |
| Autoignition temperature                                 | No data available        |
| Decomposition temperature                                |                          |
| SADT (°C)                                                | No data available        |
| pH                                                       | No data available        |
| pH (as aqueous solution)                                 | No data available        |
| Kinematic viscosity                                      | No data available        |
| Dynamic viscosity                                        | No data available        |
| Solubility                                               | No data available        |
| Vapor pressure                                           | No data available        |
| Density and/or relative density                          | No data available        |
| Bulk density                                             | No data available        |
| Liquid Density                                           | No data available        |
| Vapor density                                            | No data available        |
| Particle characteristics                                 |                          |
| Particle Size                                            | No information available |
| Particle Size Distribution                               | No information available |

## 9.2. Other information

|                   |         |
|-------------------|---------|
| Molecular formula | Mixture |
| Molecular weight  | Mixture |

### 9.2.1. Information with regard to physical hazard classes

No information available

### 9.2.2. Other safety characteristics

No information available

## **Section 10: STABILITY AND REACTIVITY**

### 10.1. Reactivity

Reactivity No information available.

### 10.2. Chemical stability

Stability Stable under normal conditions.

#### Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

### 10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

### 10.4. Conditions to avoid

Conditions to avoid Fine particles (such as mists) may fuel fires/explosions.

### 10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

### 10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 10 / 16

Version 3

## Section 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

**General Information:** There are no data for this formulation. The information included in this section describes the potential hazards of the individual ingredients

**Short term** Harmful if swallowed, May cause mild eye irritation. May cause slight skin irritation. (based on components) Drugs of this class have been associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure.

**Known Clinical Effects:** Adverse effects associated with therapeutic use include dizziness, nervousness, agitation, drowsiness, apprehension, euphoria, blurred/double vision, slurred speech, tremors, convulsions, and seizure. Respiratory depression and arrest may follow. Other, more serious effects seen with IV use of this drug, particularly when it is administered rapidly, are cardiovascular collapse, central nervous system depression, and/or hypotension.

|                                          |                                                                   |
|------------------------------------------|-------------------------------------------------------------------|
| <b>Acute toxicity</b>                    | Based on available data, the classification criteria are not met. |
| <b>Serious eye damage/eye irritation</b> | Based on available data, the classification criteria are not met. |
| <b>Skin corrosion/irritation</b>         | Based on available data, the classification criteria are not met. |
| <b>Respiratory or skin sensitization</b> | Based on available data, the classification criteria are not met. |
| <b>STOT - single exposure</b>            | Based on available data, the classification criteria are not met. |
| <b>STOT - repeated exposure</b>          | Based on available data, the classification criteria are not met. |
| <b>Reproductive toxicity</b>             | Based on available data, the classification criteria are not met. |
| <b>Germ cell mutagenicity</b>            | Based on available data, the classification criteria are not met. |
| <b>Carcinogenicity</b>                   | Based on available data, the classification criteria are not met. |
| <b>Aspiration hazard</b>                 | Based on available data, the classification criteria are not met. |

### Acute Toxicity: (Species, Route, End Point, Dose)

#### Lidocaine Hydrochloride

Rat Oral LD50 317 mg/kg  
Rat Para-periosteal LD50 25 mg/kg  
Rat Intraperitoneal LD50 133 mg/kg  
Mouse Oral LD50 292 mg/kg  
Mouse Intravenous LD50 19.5 mg/kg

#### SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m<sup>3</sup>  
Rat Oral LD 50 3 g/kg  
Mouse Oral LD 50 4 g/kg  
Rabbit Dermal LD 50 > 10 g/kg

#### Sodium hydroxide

Mouse IP LD50 40 mg/kg

#### Epinephrine

Rat Dermal LD50 62 mg/kg  
Rat Oral LD50 30 mg/kg

| Chemical name            | Oral LD50               | Dermal LD50              | Inhalation LC50         |
|--------------------------|-------------------------|--------------------------|-------------------------|
| Water                    | > 90 mL/kg ( Rat )      | -                        | -                       |
| SODIUM CHLORIDE          | = 3550 mg/kg ( Rat )    | > 10000 mg/kg ( Rabbit ) | > 42 mg/L ( Rat ) 1 h   |
| Sodium metabisulfite USP | = 1310 mg/kg ( Rat )    | > 2000 mg/kg ( Rat )     | -                       |
| Sodium hydroxide         | = 325 mg/kg ( Rat )     | = 1350 mg/kg ( Rabbit )  | -                       |
| + Hydrochloric Acid      | 238 - 277 mg/kg ( Rat ) | > 5010 mg/kg ( Rabbit )  | = 1.68 mg/L ( Rat ) 1 h |

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 11 / 16

Version 3

## Irritation / Sensitization: (Study Type, Species, Severity)

### Lidocaine Hydrochloride

Eye Irritation Rabbit Mild

Skin Irritation Rabbit Mild

### SODIUM CHLORIDE

Skin irritation Rabbit Mild

Eye irritation Rabbit Mild

### Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

### + Hydrochloric Acid

Skin irritation Severe

Eye irritation Severe

## Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

### Lidocaine Hydrochloride

Embryo / Fetal Development Rat Subcutaneous 30 mg/kg NOAEL Not teratogenic

Embryo / Fetal Development Rat Intraperitoneal 56 mg/kg NOAEL Not Teratogenic

Embryo / Fetal Development Rat Intraperitoneal 72 mg/kg/day NOAEL Not Teratogenic

Embryo / Fetal Development Rat Intravenous 500 mg/kg/day LOAEL Fetotoxicity

Embryo / Fetal Development Rat Intraperitoneal 6 mg/kg LOAEL Developmental toxicity

### Epinephrine

Embryo / Fetal Development Rat Intravenous Dose not specified Not teratogenic

Embryo / Fetal Development Rabbit Subcutaneous 30 times human dose LOAEL Developmental toxicity

Embryo / Fetal Development Mouse Subcutaneous 7 times human dose LOAEL Developmental toxicity

## Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

### Lidocaine Hydrochloride

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative

*In Vitro* Chromosome Aberration Human Lymphocytes Negative

*In Vivo* Micronucleus Mouse Negative

### Epinephrine

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Sister Chromatid Exchange Negative with activation

Sister Chromatid Exchange Chinese Hamster Ovary (CHO) cells Equivocal without activation

### + Hydrochloric Acid

Bacterial Mutagenicity (Ames) *Salmonella* Negative

*In Vivo* Micronucleus Rat Negative

### Carcinogenicity

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

### Sodium metabisulfite USP

IARC

Group 3

### + Hydrochloric Acid

IARC

Group 3

## 11.2. Information on other hazards

### 11.2.1. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 12 / 16

Version 3

## 11.2.2. Other information

**Other adverse effects** No information available.

## **Section 12: ECOLOGICAL INFORMATION**

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

### 12.1. Toxicity

**No information available**

### 12.2. Persistence and degradability

**Persistence and degradability** No information available.

### 12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

### 12.4. Mobility in soil

**Mobility in soil** No information available.

### 12.5. Results of PBT and vPvB assessment

**PBT and vPvB assessment**

| Chemical name            | PBT and vPvB assessment                    |
|--------------------------|--------------------------------------------|
| SODIUM CHLORIDE          | Not PBT/vPvB PBT assessment does not apply |
| Sodium metabisulfite USP | Not PBT/vPvB PBT assessment does not apply |
| Sodium hydroxide         | Not PBT/vPvB PBT assessment does not apply |
| + Hydrochloric Acid      | Not PBT/vPvB PBT assessment does not apply |

### 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

### 12.7. Other adverse effects

**Other adverse effects** No information available.

**PMT or vPvM properties** Based on available data, the classification criteria are not met.

## **Section 13: DISPOSAL CONSIDERATIONS**

### 13.1. Waste treatment methods

#### **Waste from residues/unused products**

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 13 / 16

Version 3

and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

**Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.**

|                                    |                |
|------------------------------------|----------------|
| <b>UN number:</b>                  | Not applicable |
| <b>UN proper shipping name:</b>    | Not applicable |
| <b>Transport hazard class(es):</b> | Not applicable |
| <b>Packing group:</b>              | Not applicable |
| <b>Environmental Hazard(s):</b>    | Not applicable |

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### Water

|                                             |            |
|---------------------------------------------|------------|
| <b>CERCLA/SARA Section 313 de minimus %</b> | Not Listed |
| <b>California Proposition 65</b>            | Not Listed |
| <b>TSCA</b>                                 | Present    |
| <b>EINECS</b>                               | 231-791-2  |
| <b>AICS</b>                                 | Present    |

#### Lidocaine Hydrochloride

|                                             |            |
|---------------------------------------------|------------|
| <b>CERCLA/SARA Section 313 de minimus %</b> | Not Listed |
| <b>California Proposition 65</b>            | Not Listed |
| <b>TSCA</b>                                 | Present    |
| <b>EINECS</b>                               | 200-803-8  |

#### SODIUM CHLORIDE

|                                             |            |
|---------------------------------------------|------------|
| <b>CERCLA/SARA Section 313 de minimus %</b> | Not Listed |
| <b>California Proposition 65</b>            | Not Listed |
| <b>TSCA</b>                                 | Present    |
| <b>EINECS</b>                               | 231-598-3  |
| <b>AICS</b>                                 | Present    |

#### Sodium metabisulfite USP

|                                                                         |            |
|-------------------------------------------------------------------------|------------|
| <b>CERCLA/SARA Section 313 de minimus %</b>                             | Not Listed |
| <b>California Proposition 65</b>                                        | Not Listed |
| <b>TSCA</b>                                                             | Present    |
| <b>EINECS</b>                                                           | 231-673-0  |
| <b>AICS</b>                                                             | Present    |
| <b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b> | Schedule 5 |

#### Epinephrine hydrochloride

|                                             |            |
|---------------------------------------------|------------|
| <b>CERCLA/SARA Section 313 de minimus %</b> | Not Listed |
| <b>California Proposition 65</b>            | Not Listed |
| <b>TSCA</b>                                 | Present    |
| <b>EINECS</b>                               | 206-346-0  |

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 14 / 16

Version 3

Sodium hydroxide

**CERCLA/SARA Section 313 de minimus %**

**Hazardous Substances RQs**

**California Proposition 65**

**TSCA**

**EINECS**

**AICS**

**Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)**

Not Listed

1000 lb

Not Listed

Present

215-185-5

Present

Schedule 5

Schedule 6

+ Hydrochloric Acid

**CERCLA/SARA Section 313 de minimus %**

**Hazardous Substances RQs**

**California Proposition 65**

**TSCA**

**EINECS**

**AICS**

**Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)**

1.0 %

5000 lb

Not Listed

Present

231-595-7

Present

Schedule 5

Schedule 6

## National regulations

### France

#### **Occupational Illnesses (R-463-3, France)**

| Chemical name                         | French RG number |
|---------------------------------------|------------------|
| SODIUM CHLORIDE<br>7647-14-5          | RG 78            |
| Sodium metabisulfite USP<br>7681-57-4 | RG 66            |

### Germany

#### **Chemical Prohibition Ordinance (ChemVerbotsV)**

Not applicable

TRGS 905

Not applicable

### Switzerland

**Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018** Not applicable

**Storage of Hazardous Material** Not applicable

**WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20** Not applicable

**Major Accidents Ordinance SR 814.012** Not applicable

### European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

#### **Authorizations and/or restrictions on use:**

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

| Chemical name                         | Restricted substance per REACH Annex XVII | Substance subject to authorization per REACH Annex XIV |
|---------------------------------------|-------------------------------------------|--------------------------------------------------------|
| Sodium metabisulfite USP<br>7681-57-4 | 75                                        | -                                                      |
| Sodium hydroxide<br>1310-73-2         | 75                                        | -                                                      |
| + Hydrochloric Acid<br>7647-01-0      | 75                                        | -                                                      |

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 15 / 16

Version 3

## Persistent Organic Pollutants

Not applicable

## Named dangerous substances per Seveso Directive (2012/18/EU)

| Chemical name                    | Lower-tier requirements (tons) | Upper-tier requirements (tons) |
|----------------------------------|--------------------------------|--------------------------------|
| + Hydrochloric Acid<br>7647-01-0 | 25                             | 250                            |

## Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

## EU - Plant Protection Products (1107/2009/EC)

| Chemical name                | EU - Plant Protection Products (1107/2009/EC) |
|------------------------------|-----------------------------------------------|
| SODIUM CHLORIDE<br>7647-14-5 | Plant protection agent                        |

## Biocidal Products Regulation (EU) No 528/2012 (BPR)

| Chemical name                         | Biocidal Products Regulation (EU) No 528/2012 (BPR)                                                     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------|
| SODIUM CHLORIDE<br>7647-14-5          | Product-type 1: Human hygiene                                                                           |
| Sodium metabisulfite USP<br>7681-57-4 | Product-type 9: Fiber, leather, rubber and polymerized<br>materials preservatives                       |
| + Hydrochloric Acid<br>7647-01-0      | Product-type 2: Disinfectants and algacides not intended<br>for direct application to humans or animals |

## Explosives Precursors Marketing and Use (2019/1148)

Not applicable

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDSL** - Canadian Domestic Substances List/Non-Domestic Substances List

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

**IECSC** - China Inventory of Existing Chemical Substances

**KECL** - Korean Existing Chemicals Inventory

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

**NZIoC** - New Zealand Inventory of Chemicals

**TCSI** - Taiwan Chemical Substance Inventory

## 15.2. Chemical safety assessment

**Chemical Safety Report** No information available

## Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

### Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H302 - Harmful if swallowed. H300 - Fatal if swallowed. H310 - Fatal in contact with skin. H318 - Causes serious eye damage.

H314 - Causes severe skin burns and eye damage. H331 - Toxic if inhaled.

# SAFETY DATA SHEET

Product Name Lidocaine hydrochloride and epinephrine injection,  
solution (Hospira, Inc.)  
Revision date 13-Jun-2025

Page 16 / 16

Version 3

---

**Data Sources:** Publicly available toxicity information. Pfizer proprietary drug development information.  
Safety data sheets for individual ingredients.

**Reason for revision** Updated Section 2 - Hazard Identification.

**Revision date** 13-Jun-2025

**Prepared By** Pfizer Global Environment, Health, and Safety

**Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.**